We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+1.11%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.58B
AUM Growth
+$102M
(+4.1%)
Cap. Flow
+$70.6M
Cap. Flow
% of AUM
2.74%
Top 10 Holdings %
Top 10 Hldgs %
45.91%
Holding
71
New
22
Increased
18
Reduced
11
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$113M |
| 2 |
Humana
HUM
|
+$98.1M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$93.7M |
| 4 |
Elanco Animal Health
ELAN
|
+$93.5M |
| 5 |
Abbott
ABT
|
+$80.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$136M |
| 2 |
Haemonetics
HAE
|
+$99.1M |
| 3 |
AGN
Allergan plc
AGN
|
+$90.4M |
| 4 |
DexCom
DXCM
|
+$87M |
| 5 |
Medtronic
MDT
|
+$81.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.39% |
| 2 | Technology | 1.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Neurocrine Biosciences
NBIX
$18.7B
| $200M | 7.77% |
2,371,390
+855,300
| +56% | +$70.2M |
|
|
2
Humana
HUM
$44B
| $171M | 6.64% |
644,860
+386,720
| +150% | +$98.1M |
|
|
3
Edwards Lifesciences
EW
$50B
| $115M | 4.46% |
+1,866,690
| New | +$113M |
|
4
Merck
MRK
$321B
| $108M | 4.2% |
1,354,446
+37,309
| +3% | +$2.86M |
|
5
Madrigal Pharmaceuticals
MDGL
$11.4B
| $108M | 4.2% |
1,032,270
+140,280
| +16% | +$15M |
|
6
Vertex Pharmaceuticals
VRTX
$122B
| $98.7M | 3.83% |
538,440
+199,670
| +59% | +$34.9M |
|
|
7
Elanco Animal Health
ELAN
$13.2B
| $97.3M | 3.78% |
+2,879,010
| New | +$93.5M |
|
8
UnitedHealth
UNH
$383B
| $97M | 3.76% |
397,440
-159,120
| -29% | -$38.3M |
|
|
9
Abbott
ABT
$183B
| $96.2M | 3.73% |
1,144,160
+1,024,690
| +858% | +$80.7M |
|
|
10
Bristol-Myers Squibb
BMY
$132B
| $91.3M | 3.54% |
+2,012,650
| New | +$93.7M |
|
|
NVRO
11
DELISTED
NEVRO CORP.
NVRO
| $79.6M | 3.09% |
1,227,730
+970,740
| +378% | +$60.4M |
|
12
Danaher
DHR
$138B
| $72.6M | 2.82% |
572,844
-612,368
| -52% | -$72.5M |
|
|
HZNP
13
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $67.2M | 2.61% |
2,793,670
+802,341
| +40% | +$20.4M |
|
14
Boston Scientific
BSX
$68.4B
| $63.2M | 2.45% |
1,471,370
+174,410
| +13% | +$6.71M |
|
|
XENT
15
DELISTED
Intersect ENT, Inc
XENT
| $63.2M | 2.45% |
2,775,895
+203,985
| +8% | +$5.5M |
|
|
CVRS
16
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
| $59.5M | 2.31% |
19,981,655
| – | – |
|
|
AMRN
17
Amarin Corp
AMRN
$298M
| $59.1M | 2.29% |
+152,396
| New | +$55.8M |
|
18
HCA Healthcare
HCA
$85.7B
| $56.7M | 2.2% |
419,330
+272,520
| +186% | +$34.5M |
|
|
19
Medtronic
MDT
$110B
| $56.3M | 2.19% |
578,300
-890,890
| -61% | -$81.3M |
|
20
Align Technology
ALGN
$12.4B
| $56.2M | 2.18% |
+205,510
| New | +$62.1M |
|
21
Charles River Laboratories
CRL
$11.3B
| $51.7M | 2.01% |
+364,413
| New | +$49.4M |
|
22
Gilead Sciences
GILD
$163B
| $51.6M | 2% |
763,300
+139,810
| +22% | +$9.2M |
|
|
BLUE
23
DELISTED
bluebird bio
BLUE
| $46.8M | 1.82% |
28,417
+5,034
| +22% | +$8.71M |
|
24
Elevance Health
ELV
$81.6B
| $42.7M | 1.66% |
+151,220
| New | +$41.3M |
|
|
25
Haemonetics
HAE
$3.85B
| $42.1M | 1.64% |
350,190
-1,007,220
| -74% | -$99.1M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q2 2019 Portfolio in Review
As of Q2 2019, HealthCor Management held 71 positions worth $2.58B, up 4.1% from $2.48B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
HealthCor Management's Q2 2019 filing shows 22 new, 18 increased, 11 reduced and 19 closed positions. Its largest new stake was Edwards Lifesciences: 1,866,690 shares worth $115M. The largest sale was Zimmer Biomet, an estimated $136M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 87% a quarter earlier, followed by Technology.
- HealthCor Management's largest Q2 2019 buy was Edwards Lifesciences: 1,866,690 shares worth $115M.
- HealthCor Management added most to Humana in Q2 2019, an estimated $98.1M increase.
- HealthCor Management's biggest Q2 2019 reduction was Haemonetics, cutting an estimated $99.1M.
- HealthCor Management fully exited Zimmer Biomet in Q2 2019, selling an estimated $136M.
- HealthCor Management's ten largest holdings make up 46% of its $2.58B portfolio in Q2 2019.
- HealthCor Management opened 22 new positions and closed 19 in Q2 2019.
- HealthCor Management's portfolio value rose 4.1% quarter-over-quarter to $2.58B.
Based on HealthCor Management's 13F filing for Q2 2019, filed 14 Aug 2019.